Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Gilead Sciences 7.803, Becton Dickinson 4.983.
Gilead Sciences vs Becton Dickinson: Revenue Comparison
Gilead Sciences (GILD) and Becton Dickinson (BDX) are peers in Healthcare. Gilead Sciences reported revenue of $7.8B as of Q2 2026, compared with $5.0B for Becton Dickinson. Gilead Sciences leads on revenue.
Gilead Sciences's gross margin is 79.8% versus 46.5% for Becton Dickinson. Gilead Sciences's net margin is -134.5% versus 7.6% for Becton Dickinson.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Gilead Sciences, Becton Dickinson.| Metric | Gilead Sciences | Becton Dickinson |
|---|---|---|
| Market Cap | - | - |
| Revenue | $7.80B | $4.98B |
| Cost of Revenue | $1.58B | $2.67B |
| Gross Profit | $6.22B | $2.31B |
| Operating Income | $-10.39B | $663.00M |
| Net Income | $-10.50B | $377.00M |
| R&D Expense | $1.76B | $258.00M |
| Earnings Per Share | -$8.45 | $1.37 |
| Gross Margin | 79.8% | 46.5% |
| Operating Margin | -133.2% | 13.3% |
| Net Profit Margin | -134.5% | 7.6% |
| Free Cash Flow | $3.69B | $509.00M |
| Cumulative Free Cash Flow | $155.83B | $39.60B |
| Operating Cash Flow | $3.57B | $652.00M |
| Cash & Equivalents | $3.18B | $708.00M |